Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
نویسندگان
چکیده
M/78 Palate Y (5 years earlier) CRF, AVR 2160 36 Cure 20 days/10 months M/76 Palate/oropharynx Y (1 years earlier) CRF 2064 48 Cure 13 days/14 months M/54 Nose Y (1 years earlier) ARF 2600 42 Cure 16 days/7 months M/72 Larynx Y (2 years earlier) ARF 2000 35 Cure 15 days/13 months F/55 Nose/palate Y (1 years earlier) ARF 2016 42 Cure 17 days/9 months Mean ... ... ... 2168 40.6 ... 16 days/6.6 months
منابع مشابه
Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis.
PURPOSE OF REVIEW Several lipid-based formulations of the antifungal and antiparasitic drug amphotericin B are now available on the market. The purpose of this review is to assess their efficacy against leishmaniasis in both experimental and clinical settings, and to point out new developments in the formulation of this antibiotic. RECENT FINDINGS The development of resistance to pentavalent ...
متن کاملActivity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis.
Standard therapy of human visceral leishmaniasis with parenteral pentavalent antimonial agents is generally curative but has the disadvantages of a 28-day treatment course, occasional treatment failures, and toxicity. The antifungal and antileishmanial agent amphotericin B has been complexed with lipids to develop a less toxic formulation of amphotericin B. Because lipid particles are phagocyti...
متن کاملEvaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model
BACKGROUND & OBJECTIVES Current therapy for leishmaniasis is limited and unsatisfactory. Amphotericin B, a second-line treatment is gradually replacing antimonials, the first-line treatment and is used as the preferred treatments in some regions. Though, presently it is the only drug with highest cure rate, its use is severely restricted by its acute toxicity. In the present study novel lipid-a...
متن کاملTwo doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
To evaluate the efficacy of a short course of a lipid formulation of amphotericin B (L-AmB) for the treatment of Mediterranean visceral leishmaniasis (VL), an open prospective study was conducted. Forty-one children with parasitologically confirmed leishmaniasis received L-AmB, 10 mg/kg daily for 2 days. The comparison groups were 30 children who, in a previous study, were treated with L-AmB, 4...
متن کاملAmphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
In Bihar, India, where visceral leishmaniasis is hyperendemic, amphotericin B deoxycholate is now first-line parenteral treatment. To test the efficacy of amphotericin B deoxycholate versus that of its lipid formulations, Indian patients were randomized to receive treatment with amphotericin B deoxycholate (1 mg/kg on alternate days for 30 days; n=51), liposomal amphotericin B (2 mg/kg per day ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
دوره 44 2 شماره
صفحات -
تاریخ انتشار 2007